CAMBRIDGE, Mass., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, announced today that it will host a live webcast to present and discuss the newly disclosed, late-breaking 48-week Phase 3 clinical data in China for...

People

6 Energy-Saving Tips

The Healing Wave Under Review: Neural Entrainment Soundwave Audio Track to...

PrimeBiome: The Doctor-Endorsed Skin-Gut Gummies Backed by Science for Women

Pacific Prime Publishes Guide to the Leading International Health Insurance Companies...

Cerebral Palsy vs. ALS

Personalized/Customized Skin Care Market Report 2025-2034 – AI-Powered Skin Diagnostics and...

Ceramic Tableware Market Report 2025: Industry Set to Reach $22.2 Billion...

Luxury Rigid Box Market Size to Elevate USD 6.70 Bn by...

Fast Lean Pro Under Review: Best Intermittent Fasting Support Supplement for...

Sacred Journey Recovery in Vista, California, Celebrates Transformative Impact on Men’s...

iGenics Under Review: The Blurry Vision Breakthrough for Eye Health with...

Featured

Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept...

6 Energy-Saving Tips

Saudia Unveils SV Lifestyle Brand at Riyadh Fashion Week

All Star Digital and Dart Co Launch One Hitters: Exclusive Partnership...

Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept...